Clinical Trial Update: Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine in combination with eribulin for second-line HER2-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Eribulin (eribulin mesilate)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University | Conditions: HER2-negative Breast Cancer | Phase 2 | Status: UNKNOWN